india pharma

India Pharma Industry Faces Raw Material Crunch as Government Restricts Ammonia Supply

India's pharmaceutical industry faces a potential raw material crunch after the department of fertilizers issued an advisory restricting surplus ammonia sales to the fertiliser sector. The directive mandates urea manufacturing units sell surplus ammonia strictly for fertiliser production, prioritising P&K and NPK manufacturers of subsidised fertilisers. Pharma executives warn the move could disrupt domestic API production, cause medicine shortages and affect India's export commitments, as ammonia is a critical input with limited alternative sourcing options.